Tin tức & Cập nhật

Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.

Treatment with dostarlimab combined with carboplatin‒paclitaxel significantly improves overall survival (OS) among patients with primary advanced or recurrent endometrial cancer (EC), with no new safety signals, results of the RUBY trial have shown.

In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.

In a prespecified secondary analysis of the SELECT trial, long-term treatment with semaglutide allows more patients with prediabetes to regress to normoglycaemia while reducing progression to diabetes in some patients. However, semaglutide does not slow glycaemic progression over time.

Two new compounds that are set to introduce advancements in the treatment landscape for Alzheimer's disease were approved by the US FDA within 1 month